Raymond James Reaffirms Buy Rating for Masimo (NASDAQ:MASI)

Raymond James restated their buy rating on shares of Masimo (NASDAQ:MASI) in a research report released on Friday morning, Stock Target Advisor reports.

MASI has been the subject of several other reports. ValuEngine lowered Masimo from a buy rating to a hold rating in a research note on Friday, May 1st. Stifel Nicolaus lifted their price target on shares of Masimo from $200.00 to $245.00 and gave the company a buy rating in a research report on Wednesday, April 29th. UBS Group increased their price objective on shares of Masimo from $207.00 to $245.00 and gave the stock a buy rating in a research report on Thursday, April 30th. BidaskClub downgraded shares of Masimo from a buy rating to a hold rating in a research note on Saturday. Finally, Needham & Company LLC cut shares of Masimo from a buy rating to a hold rating in a research report on Monday, April 20th. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock has an average rating of Buy and an average target price of $208.33.

Shares of NASDAQ:MASI opened at $219.73 on Friday. The firm has a market cap of $11.73 billion, a price-to-earnings ratio of 59.55, a PEG ratio of 3.19 and a beta of 0.91. The stock’s 50-day moving average price is $231.59 and its two-hundred day moving average price is $190.86. Masimo has a 12-month low of $139.36 and a 12-month high of $258.00.

Masimo (NASDAQ:MASI) last released its earnings results on Tuesday, April 28th. The medical equipment provider reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.91 by $0.06. The firm had revenue of $269.63 million during the quarter, compared to the consensus estimate of $268.40 million. Masimo had a net margin of 21.66% and a return on equity of 17.05%. Masimo’s revenue was up 16.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.79 earnings per share. On average, equities analysts predict that Masimo will post 3.14 earnings per share for the current year.

In other Masimo news, EVP Yongsam Lee sold 10,000 shares of Masimo stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $185.01, for a total transaction of $1,850,100.00. Following the sale, the executive vice president now directly owns 85,000 shares in the company, valued at approximately $15,725,850. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jon Coleman sold 2,000 shares of Masimo stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $190.00, for a total value of $380,000.00. Following the sale, the insider now owns 14,465 shares in the company, valued at $2,748,350. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 351,114 shares of company stock valued at $68,294,418. Company insiders own 11.50% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. increased its position in shares of Masimo by 2.0% in the 1st quarter. BlackRock Inc. now owns 6,678,471 shares of the medical equipment provider’s stock worth $1,182,890,000 after purchasing an additional 133,750 shares during the last quarter. Wellington Management Group LLP grew its stake in Masimo by 13.5% in the first quarter. Wellington Management Group LLP now owns 2,144,987 shares of the medical equipment provider’s stock worth $379,921,000 after purchasing an additional 254,661 shares in the last quarter. Citigroup Inc. grew its stake in Masimo by 165.1% in the fourth quarter. Citigroup Inc. now owns 1,535,753 shares of the medical equipment provider’s stock worth $242,741,000 after purchasing an additional 956,488 shares in the last quarter. Invesco Ltd. increased its holdings in Masimo by 5.5% in the first quarter. Invesco Ltd. now owns 1,481,756 shares of the medical equipment provider’s stock valued at $262,449,000 after buying an additional 77,080 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its stake in Masimo by 24.6% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,330,632 shares of the medical equipment provider’s stock valued at $210,320,000 after buying an additional 262,920 shares in the last quarter. Hedge funds and other institutional investors own 84.48% of the company’s stock.

About Masimo

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Featured Article: How does inflation affect different investments?

Analyst Recommendations for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.